公开(公告)号：WO2017009804A1

公开(公告)日：2017-01-19

申请号：PCT/IB2016/054219

申请日：2016-07-14

Applicant: ABBVIE S.Á.R.L. ,  GALAPAGOS NV

Inventor： ALTENBACH, Robert J. ,  BOGDAN, Andrew ,  COWART, Marlon D. ,  ESMIEU, William Ramesh ,  GFESSER, Gregory A. ,  GRESZLER, Stephen N. ,  KOENIG, John R. ,  KYM, Philip R. ,  LIU, Bo ,  MALAGU, Karine Fabienne ,  PATEL, Sachin V. ,  SCANIO, Marc J. ,  SEARLE, Xenia B. ,  VOIGHT, Eric ,  WANG, Xueqing ,  YEUNG, Ming C.

IPC: C07D317/70 ,  C07D405/12 ,  C07D407/12 ,  C07D493/04 ,  C07D519/00 ,  A61K31/36 ,  A61K31/404 ,  A61K31/426 ,  A61K31/433 ,  A61K31/443 ,  A61K31/4184 ,  A61K31/501 ,  A61K31/497 ,  A61P11/00

CPC classification number: C07D493/04 ,  A61K31/357 ,  A61K31/397 ,  A61K31/433 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/5377 ,  A61K45/06 ,  C07D317/70 ,  C07D405/12 ,  C07D407/12 ,  C07D519/00

Abstract: The present invention provides for compounds of formula (I) wherein X, Y, and R 1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中X，Y和R 1具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗由 CFTR，包括囊性纤维化，Siegren综合征，胰腺功能不全，慢性阻塞性肺病和慢性阻塞性气道疾病。 还提供了由一种或多种式（I）化合物组成的药物组合物。